Am J Transplant, Volume 5, Suppl 3 Archives - Page 58 of 170 - ATC Abstracts

2015 American Transplant Congress
The Impact of Therapy On the Inflammatory Infiltrate in Renal Allografts With Acute and Chronic Antibody Mediated Rejection
W. Mulley,^1,2 D. Nikolic-Paterson,^1,2 A. Longano,³ Y. Han,¹ F. Ma,¹ J. Kanellis,^1,2 S. Ramessur.^1,2
¹Department of Nephrology, Monash Health, Clayton, Vic, Australia; ²Department of Medicine, Monash University, Clayton, Vic, Australia; ³Department of Pathology, Monash Health, Clayton, Vic, Australia.
Little is known about the effect of usual treatment for acute and chronic antibody mediated rejection (aAMR and cAMR) on inflammatory cells within the allograft.…
2015 American Transplant Congress
First Clinical Data With an Improved C1q-Luminex® Assay
A. Roodenburg,² J. Bamoulid,¹ O. Staeck,¹ C. Schoenemann,² N. Lachmann,² K. Budde.¹
¹Nephrology, Charite Hospital, Berlin, Germany; ²HLA Laboratory, Charite Hospital, Berlin, Germany.
Background: Chronic allograft dysfunction remains the main obstacle for long-term success of kidney transplantation. Immunological factors, in particular HLA-antibodies, contribute to long-term allograft loss. Identification…
2015 American Transplant Congress
Alemtuzumab in Elderly Renal Transplant Recipients Is Not Associated With a Poor Outcome
D.-A. Moutzouris, L. Koizia, M. Willicombe, R. Corbett, N. Duncan, J. Galliford, A. McLean, D. Taube.
Imperial College Renal and Transplant Centre, Hammersmith Hospital, London, United Kingdom.
The use and choice of induction immunosuppression in elderly kidney recipients remains unresolved. Alemtuzumab has been associated with a higher risk of death and graft…
2015 American Transplant Congress
Early Use of Anti-Lymphocyte Antibody in Kidney Transplant Recipients With Delayed Graft Function Can Produce Desirable Post-Transplant Results
J. Lee, J. Lee, D. Joo, K. Huh, S. Kim, Y. Kim, M. Kim.
Department of Transplantation Surgery, Yonsei University Health System, Seoul, Republic of Korea.
Proper management of delayed graft function (DGF) is essential for successful post-transplant result in deceased donor kidney transplantation. We compared the effect of anti-lymphocyte antibody…
2015 American Transplant Congress
Diabetes Mellitus and Prediabetes On Kidney Transplant Waiting List – Prevalence, Metabolic Phenotyping and Risk Stratification Approach
M. Guthoff,¹ D. Vosseler,¹ J. Langanke,¹ S. Nadalin,² A. Königsrainer,² H.-U. Häring,¹ A. Fritsche,¹ N. Heyne.¹
¹Dept. of Endocrinology and Diabetology, Angiology, Nephrology and Clinical Chemistry, University of Tübingen, Tübingen, Germany; ²Dept. of General, Visceral and Transplant Surgery, University of Tübingen, Tübingen, Germany.
Purpose: Diabetes mellitus (DM), the most common cause of ESRD, limits access to transplantation and impairs patient and allograft outcome. Prediabetes is an independent risk…
2015 American Transplant Congress
Outcomes of Hepatitis C Virus (HCV) Treatment Following Liver Transplantation in the Era of Direct-Acting Antiviral Medications
S. Baggett,¹ D. Jones,¹ M. Shoreibah.²
¹Department of Pharmacy, UAB Hospital, Birmingham, AL; ²Department of Gastroenterology, UAB Hospital, Birmingham, AL.
BACKGROUND: The treatment of HCV is one of the most rapidly changing areas of medical practice. These agents have been shown to be safe and…
2015 American Transplant Congress
Pharmacist-Led Renal-Sparing Conversion to Everolimus After Liver Transplantation
T. Horwedel,¹ L. Bowman,¹ W. Chapman,² J. Hagopian.¹
¹Barnes-Jewish Hospital, St. Louis, MO; ²Washington University in St. Louis, St. Louis, MO.
Purpose: Preservation of renal function following orthotopic liver transplantation (OLT) through calcineurin inhibitor (CNI)-minimization is an established clinical objective. The use of everolimus (EVR) to…
2015 American Transplant Congress
Should We Ever Pay Living Kidney Donors? Focus Group Study of Public Opinion
A. Tong,^1,2 A. Ralph,^1,2 J. Chapman,³ G. Wong,^1,2,3 J. Gill,⁴ M. Josephson,⁵ C. Hanson,^1,2 J. Craig.^1,2
¹School of Public Health, The University of Sydney, Sydney, Australia; ²Centre for Kidney Research, The Children's Hospital at Westmead, Sydney, Australia; ³Centre for Transplant and Renal Research, Westmead Hospital, Sydney, Australia; ⁴Division of Nephrology, University of British Columbia, Vancouver, Canada; ⁵Department of Medicine, University of Chicago, Chicago.
Background: The unmet demand for kidney transplantation has generated intense controversy about introducing incentives for living kidney donors to increase donation rates. Such debates may…
2015 American Transplant Congress
PI3Kα and STAT1 Interplay Regulates Human Mesenchymal Stem Cell Immune Polarization
E. Kefalogianni,¹ M. Mounayar,² B. Smith,² J. Azzi,² L. Chabtini,² P. Fiorina,² M. Kraus,³ R. Briddell,⁴ W. Fodor,⁵ A. Herrlich,¹ R. Abdi.²
¹Brigham and Women's Hospital, Harvard Medical School, Boston, MA; ²Transplantation Research Center, Brigham and Women's and Children's Hospital, Harvard Medical School, Boston, MA; ³Viacord LLC, a PerkinElmer Company, Cambridge, MA; ⁴ViaCord Processing Lab, Viacord LLC, a PerkinElmer Company, Hebron, KY; ⁵The Cell Therapy Group, Madison, CT.
The immunomodulatory capacity of mesenchymal stem cells (MSC) is critical for their use in therapeutic applications. MSC response to specific inflammatory cues allows them to…
2015 American Transplant Congress
HO-1 Modified Macrophages Promote Autophagy by Activating Sirt1/TGF-β/Smad4 Signaling in Ischemia-Stressed Mouse Liver Transplants
S. Yue, J. Huang, K. Nakamura, M. Zhou, X.-D. Shen, R. Busuttil, B. Ke, J. Kupiec-Weglinski.
Dumont-UCLA Transplant Ctr, Dept. of Surgery, David Geffen School of Medicine at UCLA, Los Angeles, CA.
Background: Although heme oxygenase-1 (HO-1) is known to induce alternative macrophage activation towards an anti-inflammatory M2 phenotype, the underlying mechanisms remain elusive. Autophagy may play…